J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
Abnormal prenatal blood results are indicative of hidden cancers in pregnant women, researchers at the US nation’s medical research agency, the National Institutes.
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.
Kezar Life Sciences Inc., a US-based biotechnology company, has stopped a trial in patients with a type of kidney disease after four people.
HQ Team July 16, 2024: A new study by Northwestern Medicine and Brigham and Women’s Hospital researchers has identified a possible cause for.
HQ Team November 28, 2023: Argenx SE, a Belgian biopharmaceutical announced that its experimental drug Vyvgart Hytrulo failed in trials in treating immune.
HQ Team November 28, 2023: An escalating global crisis is unfolding as an increasing number of individuals grapple with autoimmune diseases, conditions wherein.
HQ Team Sept 14, 2023: Researchers at the University of Chicago’s Pritzker School of Molecular Engineering have developed an “inverse vaccine” to combat.
Moderna, a US-based biotechnology company, announced a $35 million licensing deal with cancer-focused drugmaker CytomX to develop messenger RNA therapies.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com